In the Clinical/Scientific Note “A case of CIDP concurrent with MGUS IgG kappa responsive to autologous stem cell transplantation” by Colucci et al,1 the legend of figure 1 should include the ᴥ symbol before “preventive hematopoietic stem cell mobilization and collection.” The publisher regrets the error.
Further, the final sentence of the Discussion section should read, “Our report may as well suggest investigating other novel myeloma-specific therapeutic approaches in clinically refractory CIDP with concurrent MGUS, e.g., the anti-CD38 antibody daratumumab and venetoclax, a selective, orally bioavailable B-cell lymphoma 2 (BCL-2) inhibitor that induces cell death in multiple myeloma cells, particularly in those harboring t (11; 14), that express high levels of BCL-2 relative to BCL-extra large (BCL-XL) and myeloid cell leukemia 1 (MCL-1).” The authors regret the error.
- © 2021 American Academy of Neurology
Reference
- 1.↵
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.